One day, cancer treatment regimens might include vaccines specially tailored to each patient. In a small preliminary study published in Science, researchers report successful use of these vaccines in 3 patients.
One day, cancer treatment regimens might include vaccines specially tailored to each patient. In a small preliminary study published in Science, researchers report successful use of these vaccines in 3 patients.
To help the melanoma patients fight off their cancers, the researchers sequenced the genomes of their tumors. They used this genetic information to figure out what peptides (chains of amino acids) known as neoantigens would show up on the surface of the tumor.
"You can think of a neoantigen as a flag on each cancer cell," first author Beatriz Carreno, an associate professor at Washington University School of Medicine in St. Louis, said in a statement. "Each patient's melanoma can have hundreds of different flags."
Read more at The Washington Post: http://wapo.st/1DCckND
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More